[1]李鸿博,石丹宁,张杜娟,等.基于网络药理学及分子对接技术探究三棱-莪术配伍在卵巢癌辅助治疗中的作用机制[J].西部中医药,2024,37(02):69-76.[doi:10.12174/j.issn.2096-9600.2024.02.15]
　LI Hongbo,SHI Danning,ZHANG Dujuan,et al.Study on the Mechanism of Sanleng-Ezhu in the Adjuvant Treatment of Ovarian Cancer Based on Network Pharmacology and Molecular Docking[J].Western Journal of Traditional Chinese Medicine,2024,37(02):69-76.[doi:10.12174/j.issn.2096-9600.2024.02.15]
点击复制

基于网络药理学及分子对接技术探究三棱-莪术配伍在卵巢癌辅助治疗中的作用机制
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
37
期数:
2024年02期
页码:
69-76
栏目:
二次研究
出版日期:
2024-02-15

文章信息/Info

Title:
Study on the Mechanism of Sanleng-Ezhu in the Adjuvant Treatment of Ovarian Cancer Based on Network Pharmacology and Molecular Docking
作者:
李鸿博1, 石丹宁3, 张杜娟1, 张璐2, 李翡2
1.陕西中医药大学附属医院，陕西 咸阳 712000
2.陕西中医药大学，陕西 咸阳 712046
3.北京中医药大学生命科学学院，北京 100029
Author(s):
LI Hongbo1, SHI Danning3, ZHANG Dujuan1, ZHANG Lu2, LI Fei2
1.Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang 712000, China
2.Shaanxi University of Chinese Medicine, Xianyang 712046, China
3.School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China
关键词:
卵巢癌; 三棱; 莪术; 网络药理学; 分子对接
Keywords:
ovarian cancer; network pharmacology; molecular docking
分类号:
R737.31
DOI:
10.12174/j.issn.2096-9600.2024.02.15
文献标志码:
A
摘要:
目的基于网络药理学及分子对接技术，探究三棱-莪术药对在辅助治疗卵巢癌中的作用机制。 方法活性成分及其作用靶点收集自中药系统药理学分析平台，卵巢癌相关靶点收集自Genecard数据库。上述靶点取交集后，结合STRING数据库及Cytoscape软件构建PPI网络。应用R及Cytoscape软件整合构建中药-活性成分-疾病-靶点网络。同时，应用R软件进行基因本体论（gene ontology，GO）功能富集、京都基因与基因组百科全书（kyoto encyclopedia of genes and genomes，KEGG）通路富集，并通过Cytoscape/CluGO进行KEGG通路聚类分析。综合分析各网络，获取关键靶点及其对应活性成分后应用Autodock vina及Pymol等软件进行分子对接及可视化研究。 结果本研究在三棱-莪术药对中，共获得8个活性成分，164个作用靶点，Genecards数据库获得1540个符合条件的卵巢癌相关靶点。取交集获得27个三棱-莪术药对治疗卵巢癌的潜在靶点。分析PPI网络并获取关键靶点为CASP3、ESR1、JUN、PTGS2、AR、MAPK14、PGR、CASP8、CASP9、CAS及PPARG。GO及KEGG分析表明相关作用机制可能涉及凋亡、白细胞介素17（interleukin-17，IL-17）信号通路、乙肝信号通路、雌激素信号通路、甲状腺激素信号通路，卵巢类固醇等多条信号通路。分子对接表明核心成分芒柄花黄素、β-谷甾醇、常春藤皂苷元与关键靶点结合性良好，其中各活性成分与PTGS2结合最佳，结合能均小于-9.0 kcal/mol。 结论该研究初步揭示了三棱-莪术药对治疗卵巢癌的药理机制，这为后期探究该药对及其所在复方治疗卵巢癌提供了较为系统的依据。
Abstract:
ObjectiveTo survey the mechanism of Sanleng-Ezhu in the adjuvant treatment of ovarian cancer based on network pharmacology and molecular docking. MethodsActive compounds and their potential targets were collected from TCMSP database, ovarian cancer (OC) related targets were obtained from Genecard database. After intersecting the targets mentioned above, PPI network was constructed by combining STRING database and Cytoscape software. R and Cytoscape software were used to construct TCM - active compounds - disease - target network. Meanwhile, R software was applied to perform GO enrichment and KEGG pathway enrichment, Cytoscape software/CluGO was used to carry out cluster analysis of KEGG pathway. Comprehensive analysis of all the network obtained the key targets and the corresponding active ingredients, Autodock vina and Pymol were exploited to conduct molecular docking and visualization study. ResultsIn the drug pair, eight active ingredients and 164 targets were obtained in the study, 1540 OC related targets in line with the requirements were gained from Genecards database. 27 potential targets of the drug pair for the treatment of ovarian cancer were obtained after intersection. The key targets obtained by analyzing PPI network were CASP3, ESR1, JUN, PTGS2, AR, MAPK14, PGR, CASP8, CASP9, CAS and PPARG. GO and KEGG analysis displayed that the relevant mechanism may involve apoptosis, IL-17 signaling pathway, hepatitis B signaling pathway, estrogen signaling pathway, thyroid hormone signaling pathway, ovarian steroids. Molecular docking indicated that the core com-ponents formononetin, β-sitosterol and hederagenin had good binding with key targets, among them, different active ingredients showed the best binding with PTGS2, and binding energy was less than -9.0 kcal/mol. ConclusionThe current study has preliminarily revealed the pharmacological mechanism of the treatment of ovarian cancer by Sanleng-Ezhu, which could provide a systematic basis for further exploration of the couplet medicine and its compounds in the treatment of the disease.

相似文献/References:

[1]李晶,刘小军,赵达△.康莱特软胶囊联合化疗治疗晚期卵巢癌的临床研究[J].西部中医药,2013,26(01):1.
　LI Jing,LIU Xiaojun,ZHAO Da.Clinical Study on KangLaiTe Soft Capsule and Chemotherapy in Treating Ovarian Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(02):1.
[2]郭强蕊.CT诊断在卵巢癌和宫颈癌放射治疗前后的临床运用价值[J].西部中医药,2015,28(01):125.
[3]狄晓鸿,吕瑞.TP化疗方案联合参芪扶正注射液治疗晚期卵巢癌的临床观察[J].西部中医药,2015,28(08):1.
[4]艾敬,王红燕,张硕.Orem自理模式对卵巢癌化疗患者生活质量的影响[J].西部中医药,2017,30(04):127.
　AI Jing,WANG Hongyan,ZHANG Shuo.Effect of Orem Self-care Model on Life Quality of Patients with Chemotherapy of Ovarian Cancer[J].Western Journal of Traditional Chinese Medicine,2017,30(02):127.

备注/Memo

备注/Memo:
李鸿博（1993—），男，硕士学位，医师。研究方向：妇科肿瘤的中西医结合治疗。陕西省重点研发计划项目（2020SF-052）。
更新日期/Last Update: 2024-02-15